News

Waldencast Shares Key Insights from Q2 and Q3 2025 Updates

Waldencast Shares Key Insights from Q2 and Q3 2025 Updates

Waldencast Reports Q2 2025 Results with Insights for Q3 2025

Waldencast plc (NASDAQ: WALD), a prominent player in the global beauty and wellness industry, has shared its operating results for the second quarter of 2025, highlighting a strategic focus on growth and innovation. This report showcases a robust 5.6% year-over-year increase in net revenue, reaching $66.8 million, and underscores the company's commitment to long-term value generation.

Transformative Growth and Strategic Initiatives

Leading the charge, Obagi Medical has experienced notable performance improvements, fueled by transformative initiatives and expanding market reach. Not only has Obagi gained traction in direct-to-consumer e-commerce channels, but it also showcases impressive double-digit growth in international markets. Meanwhile, Waldencast's Milk Makeup brand has witnessed healthy growth in the U.S., driven by expansion into new retail channels and product innovations.

Performance Insights from Q2 2025

Reflecting on the results from the first half of the financial year, Waldencast achieved a total net revenue of $132.3 million, which marks a modest year-over-year growth of 0.5%. This performance is particularly noteworthy considering the challenges faced in international markets.

Operational Efficiencies and Strategic Acquisitions

Throughout Q2 and Q3, Waldencast has undertaken significant initiatives, including the successful acquisition of Novaestiq, aimed at enhancing its offerings in the medical aesthetics sector. This acquisition allows Waldencast to double its addressable market in the U.S. and strengthen its innovative product line, including the newly FDA-approved Obagi Saypha® products.

The company’s proactive measures in bolstering its balance sheet, particularly through the sale of the Obagi Japan trademark rights and refinancing of its credit facilities, have positioned Waldencast for sustainable growth and operational efficiency.

Outlook for Q3 2025: Navigating Challenges and Opportunities

As Waldencast enters the third quarter, it faces a contrasting landscape. Despite Milk Makeup's ongoing innovations, the brand is expected to see softer performance compared to the previous year's record launches, especially in international markets. Nevertheless, the company remains dedicated to enhancing its marketing strategies and expanding its product range to reclaim momentum.

Financial Review and Expectations Moving Forward

The updated fiscal outlook for 2025 reflects Waldencast’s adaptive strategies in response to market trends. An anticipated revenue outlook aligning closely with 2024 reflects ongoing investments in product innovation, particularly for Milk Makeup. The Adjusted EBITDA Margin is projected to remain in the high single digits, indicating stable operational efficiency despite external pressures.

Future Growth Trajectory

Waldencast’s leadership remains optimistic about its growth trajectory, emphasizing the importance of digital capabilities and process efficiencies. The commitment to sustainability and market responsiveness will be key as the company seeks to navigate challenges posed by shifts in consumer behavior and international market dynamics.

Frequently Asked Questions

What were Waldencast’s net revenues for Q2 2025?

Waldencast reported a net revenue of $66.8 million for Q2 2025, representing a 5.6% increase compared to the previous year.

How is Obagi Medical performing in terms of brand awareness?

Obagi Medical has achieved the leading position in unaided brand awareness within its competitive set, showcasing significant growth, especially in e-commerce and international markets.

What challenges is Milk Makeup facing going into Q3 2025?

Milk Makeup is experiencing softer performance in international markets and is facing challenges compared to last year’s successful product launches, leading to revenue adjustments.

What initiatives are being pursued for future growth?

Waldencast is focusing on expanding digital capabilities, strengthening its marketing strategies, and continuing to innovate its product lines to drive consumer engagement and sales growth.

What is Waldencast’s Adjusted EBITDA Margin outlook?

The Adjusted EBITDA Margin for Waldencast is expected to remain in the high single digits, reflecting ongoing operational efficiencies despite external market challenges.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

LKQ’s Europe ERP Mess Turns Into a Credibility Test

Updated Category News Views 98

A software rollout should not be able to punch a company in the teeth twice, yet LKQ shareholders have watched precisely that ugly movie in 2026. The October 23 disclosure was a real gut-check: an immediate CEO departure, a $16 million net loss, and renewed acknowledgement that the German enterprise-resource-planning rollout was disrupting Europe. Shares fell $5.05, or...

Continue Reading
NetEase Miss Opens an Investigation, Not a Verdict

Updated Category News Views 70

A two-dollar earnings gap can make a shareholder base jumpy fast, and NetEase just handed the market a rough set of numbers to chew on. The November 19 notice says NetEase's third-quarter 2026 report missed Wall Street expectations on both earnings and revenue, followed by a sharp decline in the shares. That has prompted SueWallSt, powered by Levi & Korsinsky LLP, to...

Continue Reading
Frost & Sullivan’s 65 Years Put APAC Growth on Display

Updated Category News Views 25

A Crowded Singapore Room Says Something Singapore did not host a mere anniversary toast on November 18; it hosted a pretty revealing cross-section of the businesses trying to build, secure, cool, connect, finance, and digitize Asia Pacific and MEASA. Frost & Sullivan marked 65 years with its 2026 Best Practices Recognition banquet at Hilton Singapore Orchard, gathering...

Continue Reading
Anduin Opens Its Investor Portal Beyond Early Users

Updated Category News Views 30

Private-market paperwork has long been a swamp of portals, PDFs, email chains, and somebody chasing down a wire change at the worst possible moment. Anduin is taking a swing at that mess by opening its Investor Portal to all customers after building it with leading asset managers and operating it with their investors. The pitch is sensible: give limited partners one...

Continue Reading
Shareholder Votes Clear ODNB-NACB Merger's Final Hurdle

Updated Category News Views 69

A merger vote rarely makes anyone pound the table, but it does remove one very real way a bank deal can stumble. ODNB Financial Corporation and National Capital Bancorp, Inc. have announced that their shareholders approved the proposed merger. That is meaningful progress, plain and simple. It says the owners who get to live with the outcome have signed off on joining the...

Continue Reading
SwitchBot's Black Friday Sale Tests Smart Home Demand

Updated Category News Views 147

Holiday gadget season is where clever home-tech pitches either earn their keep or gather dust in a warehouse. SwitchBot is coming into Black Friday 2026 with discounts of up to 50% on select products, running from November 19 through Cyber Monday on November 30. The lineup is broad enough to matter: decorative color E Ink frames, automated curtains and blinds, an indoor...

Continue Reading
Adcendo’s Early Sarcoma Data Earns a Careful Look

Updated Category News Views 71

Sarcoma data rarely gives anyone permission to pound the table, yet Adcendo’s first look at ADCE-D01 deserves more than a polite nod. In advanced soft tissue sarcoma, where patients have often run through the usual options and second-line response rates historically sit around 4% to 10%, a reported 30% objective response rate on the every-two-week schedule is...

Continue Reading
MemorialCare Adds AI Guardrails for Hidden Aneurysms

Updated Category News Views 91

A brain scan ordered for one reason can suddenly expose a risk nobody knew was sitting there. That is the sober promise behind MemorialCare Neuroscience Institute's rollout of Rapid Aneurysm, an artificial-intelligence tool embedded in qualifying CTA and MRA brain scans across its inpatient and outpatient network. MemorialCare says it is the first health system in Los...

Continue Reading
Decibel's Export Engine Masks a Domestic Sales Slip

Updated Category News Views 118

Decibel’s overseas business is doing the heavy lifting, and it is not doing it quietly. Third-quarter net revenue reached $35.1 million, up 7% from a year earlier, while international sales jumped 44% to a record $12.1 million. That split matters more than the headline. Canadian adult-use sales fell 6% to $23.0 million, which means the company is proving it can find...

Continue Reading
Candel’s BLA Delay Puts Disclosure Timing Under Fire

Updated Category News Views 118

A December filing turned into a mid-2027 wait, and Candel shareholders absorbed the damage in one ugly trading session. On November 13, shares of Candel Therapeutics fell 26% after the company disclosed that its biologics license application, or BLA, for aglatimagene in prostate cancer was no longer expected in December 2026. The revised plan is to submit in the middle of...

Continue Reading

Top 5 Most Recently Viewed Articles

Mobile Homes Market Grows to $16.62B by 2031

Updated Category News Views 24

Affordable Housing Fuels Mobile Homes Market When the traditional real estate market is out of reach, what's the average Joe supposed to do? Enter the mobile home market, which is expected to leap from $11.87 billion in 2026 to a hefty $16.62 billion by 2031. That's a compound annual growth rate (CAGR) of 6.96%—not too shabby for a sector often ignored by the mainstream...

Continue Reading
KinderCare Investors Face Legal Challenges Over IPO Misrepresentation

Updated Category News Views 213

Legal Action Against KinderCare Learning Companies A securities class action lawsuit has been initiated against KinderCare Learning Companies, Inc. (NYSE: KLC) and its executives. This lawsuit centers on allegations that the company misrepresented its activities and safety records during its Initial Public Offering (IPO) in October 2024. Investors who acquired KLC common...

Continue Reading
Intec Pharma Ltd's Stock Sees Decline: A Deeper Analysis

Updated Category News Views 204

Intec Pharma Ltd Faces a Rocky Road Intec Pharma Ltd (NASDAQ: INDP) is knee-deep in trouble, with its stock diving to a brutal 52-week low of $1.20. This stark drop of 56.12% over the past year paints a dismal picture for investors scoping out this biotech player. It’s no surprise that all eyes are on INDP as it struggles to navigate these choppy waters and rebuild its...

Continue Reading
Sol Rei Wine Shines at San Francisco Wine Competition

Updated Category News Views 190

Celebrating Excellence at the San Francisco Wine Competition In an impressive display of craftsmanship and quality, Sol Rei Wine has recently achieved remarkable accolades at the esteemed San Francisco Wine Competition. This boutique, women-owned wine brand has won both Double Gold and Gold medals for their exquisite offerings: the Sol Rei Syrah and the Sol Rei Private...

Continue Reading
Insight Molecular Diagnostics Gears Up for Exciting 2026 Launch

Updated Category News Views 260

Exciting Progress Ahead for Insight Molecular Diagnostics Inc. Insight Molecular Diagnostics Inc. (NASDAQ: IMDX) is taking significant strides towards launching its innovative GraftAssureDx™ test in 2026. With anticipation building within the organization and among stakeholders, the company is preparing to submit its application for FDA approval by the year's end. This...

Continue Reading